Evidence map›Paper›PMID 36613556›Full record

ArticleInternational journal of molecular sciences2022

An Inverse Agonist GSK5182 Increases Protein Stability of the Orphan Nuclear Receptor ERRγ via Inhibition of Ubiquitination.

Soon-Young Na, Ki-Sun Kim, Yoon Seok Jung, Don-Kyu Kim, Jina Kim, Sung Jin Cho, In-Kyu Lee, Jongkyeong Chung, Jeong-Sun Kim, Hueng-Sik Choi

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Nuclear Receptors in Health and Diseases.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Soon-Young NaSchool of Biological Sciences and Technology, Chonnam National University, Gwangju 61186, Republic of Korea.
Ki-Sun KimSchool of Biological Sciences and Technology, Chonnam National University, Gwangju 61186, Republic of Korea.
Yoon Seok JungSchool of Biological Sciences and Technology, Chonnam National University, Gwangju 61186, Republic of Korea.
Don-Kyu KimDepartment of Integrative Food, Bioscience and Biotechnology, Chonnam National University, Gwangju 61186, Republic of Korea.ORCID 0000-0002-6251-6438
Jina KimNew Drug Development Center, Daegu Gyeongbuk Medical Innovation Foundation, Daegu 41061, Republic of Korea.
Sung Jin ChoCenter for Brain Disorders, Brain Science Institute, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea.
In-Kyu LeeDepartment of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu 41944, Republic of Korea.
Jongkyeong ChungSRC Center for Systems Geroscience, Institute of Molecular Biology and Genetics, School of Biological Sciences, Seoul National University, Seoul 08826, Republic of Korea.
Jeong-Sun KimDepartment of Chemistry, Chonnam National University, Gwangju 61186, Republic of Korea.
Hueng-Sik ChoiSchool of Biological Sciences and Technology, Chonnam National University, Gwangju 61186, Republic of Korea.
Chonnam National University · KRKorea Institute of Brain Science · KRKyungpook National University Hospital · KRSeoul National University · KR

Funding

Korea Health Industry Development Institute HI16C1501National Research Foundation of Korea 20110018305National Research Foundation of Korea NRF-2021R1A2C3004923
6 · The paper itself

Abstract

The orphan nuclear receptor, estrogen-related receptor γ (ERRγ) is a constitutively active transcription factor involved in mitochondrial metabolism and energy homeostasis. GSK5182, a specific inverse agonist of ERRγ that inhibits transcriptional activity, induces a conformational change in ERRγ, resulting in a loss of coactivator binding. However, the molecular mechanism underlying the stabilization of the ERRγ protein by its inverse agonist remains largely unknown. In this study, we found that GSK5182 inhibited ubiquitination of ERRγ, thereby stabilizing the ERRγ protein, using cell-based assays and confocal image analysis. Y326 of ERRγ was essential for stabilization by GSK5182, as ligand-induced stabilization of ERRγ was not observed with the ERRγ-Y326A mutant. GSK5182 suppressed ubiquitination of ERRγ by the E3 ligase Parkin and subsequent degradation. The inhibitory activity of GSK5182 was strong even when the ERRγ protein level was elevated, as ERRγ bound to GSK5182 recruited a corepressor, small heterodimer partner-interacting leucine zipper (SMILE), through the activation function 2 (AF-2) domain, without alteration of the nuclear localization or DNA-binding ability of ERRγ. In addition, the AF-2 domain of ERRγ was critical for the regulation of protein stability. Mutants in the AF-2 domain were present at higher levels than the wild type in the absence of GSK5182. Furthermore, the ERRγ-L449A/L451A mutant was no longer susceptible to GSK5182. Thus, the AF-2 domain of ERRγ is responsible for the regulation of transcriptional activity and protein stability by GSK5182. These findings suggest that GSK5182 regulates ERRγ by a unique molecular mechanism, increasing the inactive form of ERRγ via inhibition of ubiquitination.

Indexed as

Drug Inverse AgonismOrphan Nuclear ReceptorsFurylfuramideProtein StabilityTamoxifenUbiquitinationFurylfuramideGSK5182Orphan Nuclear ReceptorsTamoxifenERRγinverse agonistnuclear receptorParkinprotein stabilityubiquitination

Identifiers

PMID36613556
PMCPMC9820335
OpenAlexW4312186713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.